This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Salès F, Gore M, MacKie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A.Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. Journal of Clinical Oncology 27: 2916-2923, No. 18, 20 Jun 2009
Rights and permissions
About this article
Cite this article
QOL reduced with adjuvant peginterferon-α-2b for melanoma. Pharmacoecon. Outcomes News 581, 9 (2009). https://doi.org/10.2165/00151234-200905810-00026
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905810-00026